{"result": "(\"entity\"<|>POLYCYSTIC OVARY SYNDROME<|>EVENT<|>Polycystic Ovary Syndrome (SOP) is a hormonal disorder causing enlarged ovaries with small cysts on the outer edges, leading to various metabolic and clinical repercussions in women.)\n##\n(\"entity\"<|>TESTOSTERONE<|>ORGANIZATION<|>Testosterone is a hormone used in the treatment of transgender men to achieve virilization and amenorrhea, administered through various methods including injections and gels.)\n##\n(\"entity\"<|>BULUN SE<|>PERSON<|>Bulun SE is an author referenced in the context of the physiology and pathology of the female reproductive axis.)\n##\n(\"entity\"<|>LEGRO RS<|>PERSON<|>Legro RS is an author noted for their work on the evaluation and treatment of Polycystic Ovary Syndrome.)\n##\n(\"entity\"<|>ORTIZ-FLORES AE<|>PERSON<|>Ortiz-Flores AE is an author who has contributed to the understanding of Polycystic Ovary Syndrome in adult women.)\n##\n(\"entity\"<|>SLEEP APNEA SYNDROME<|>EVENT<|>Sleep Apnea Syndrome is a condition that can occur in individuals with Polycystic Ovary Syndrome and has implications for treatment decisions in transgender men.)\n##\n(\"entity\"<|>PANCREATITIS<|>EVENT<|>Pancreatitis is a medical condition that may have implications for treatment decisions in transgender men undergoing testosterone therapy.)\n##\n(\"entity\"<|>ISCHEMIC HEART DISEASE<|>EVENT<|>Ischemic Heart Disease is a condition that can affect treatment decisions for transgender men receiving testosterone therapy.)\n##\n(\"entity\"<|>ERYTHROCYTOSIS<|>EVENT<|>Erythrocytosis is a potential adverse effect of testosterone therapy that requires monitoring in transgender men.)\n##\n(\"relationship\"<|>TESTOSTERONE<|>POLYCYSTIC OVARY SYNDROME<|>Testosterone is used as a treatment for transgender men, which can also have implications for women with Polycystic Ovary Syndrome<|>7)\n##\n(\"relationship\"<|>BULUN SE<|>POLYCYSTIC OVARY SYNDROME<|>Bulun SE's work discusses the physiology related to conditions like Polycystic Ovary Syndrome<|>5)\n##\n(\"relationship\"<|>LEGRO RS<|>POLYCYSTIC OVARY SYNDROME<|>Legro RS's research focuses on the evaluation and treatment of Polycystic Ovary Syndrome<|>5)\n##\n(\"relationship\"<|>ORTIZ-FLORES AE<|>POLYCYSTIC OVARY SYNDROME<|>Ortiz-Flores AE has contributed to the literature on Polycystic Ovary Syndrome in adult women<|>5)\n##\n(\"relationship\"<|>SLEEP APNEA SYNDROME<|>POLYCYSTIC OVARY SYNDROME<|>Sleep Apnea Syndrome is a condition that can be associated with Polycystic Ovary Syndrome<|>4)\n##\n(\"relationship\"<|>PANCREATITIS<|>POLYCYSTIC OVARY SYNDROME<|>Pancreatitis is a condition that may be relevant in the context of treatment for individuals with Polycystic Ovary Syndrome<|>4)\n##\n(\"relationship\"<|>ISCHEMIC HEART DISEASE<|>POLYCYSTIC OVARY SYNDROME<|>Ischemic Heart Disease can have implications for treatment decisions in patients with Polycystic Ovary Syndrome<|>4)\n##\n(\"relationship\"<|>ERYTHROCYTOSIS<|>TESTOSTERONE<|>Erythrocytosis is a known risk associated with testosterone therapy, which is relevant for transgender men<|>6)\n<|COMPLETE|>", "input": "\n-Goal-\nGiven a text document that is potentially relevant to this activity and a list of entity types, identify all entities of those types from the text and all relationships among the identified entities.\n \n-Steps-\n1. Identify all entities. For each identified entity, extract the following information:\n- entity_name: Name of the entity, capitalized\n- entity_type: One of the following types: [organization,person,geo,event]\n- entity_description: Comprehensive description of the entity's attributes and activities\nFormat each entity as (\"entity\"<|><entity_name><|><entity_type><|><entity_description>)\n \n2. From the entities identified in step 1, identify all pairs of (source_entity, target_entity) that are *clearly related* to each other.\nFor each pair of related entities, extract the following information:\n- source_entity: name of the source entity, as identified in step 1\n- target_entity: name of the target entity, as identified in step 1\n- relationship_description: explanation as to why you think the source entity and the target entity are related to each other\n- relationship_strength: a numeric score indicating strength of the relationship between the source entity and target entity\n Format each relationship as (\"relationship\"<|><source_entity><|><target_entity><|><relationship_description><|><relationship_strength>)\n \n3. Return output in English as a single list of all the entities and relationships identified in steps 1 and 2. Use **##** as the list delimiter.\n \n4. When finished, output <|COMPLETE|>\n \n######################\n-Examples-\n######################\nExample 1:\nEntity_types: ORGANIZATION,PERSON\nText:\nThe Verdantis's Central Institution is scheduled to meet on Monday and Thursday, with the institution planning to release its latest policy decision on Thursday at 1:30 p.m. PDT, followed by a press conference where Central Institution Chair Martin Smith will take questions. Investors expect the Market Strategy Committee to hold its benchmark interest rate steady in a range of 3.5%-3.75%.\n######################\nOutput:\n(\"entity\"<|>CENTRAL INSTITUTION<|>ORGANIZATION<|>The Central Institution is the Federal Reserve of Verdantis, which is setting interest rates on Monday and Thursday)\n##\n(\"entity\"<|>MARTIN SMITH<|>PERSON<|>Martin Smith is the chair of the Central Institution)\n##\n(\"entity\"<|>MARKET STRATEGY COMMITTEE<|>ORGANIZATION<|>The Central Institution committee makes key decisions about interest rates and the growth of Verdantis's money supply)\n##\n(\"relationship\"<|>MARTIN SMITH<|>CENTRAL INSTITUTION<|>Martin Smith is the Chair of the Central Institution and will answer questions at a press conference<|>9)\n<|COMPLETE|>\n\n######################\nExample 2:\nEntity_types: ORGANIZATION\nText:\nTechGlobal's (TG) stock skyrocketed in its opening day on the Global Exchange Thursday. But IPO experts warn that the semiconductor corporation's debut on the public markets isn't indicative of how other newly listed companies may perform.\n\nTechGlobal, a formerly public company, was taken private by Vision Holdings in 2014. The well-established chip designer says it powers 85% of premium smartphones.\n######################\nOutput:\n(\"entity\"<|>TECHGLOBAL<|>ORGANIZATION<|>TechGlobal is a stock now listed on the Global Exchange which powers 85% of premium smartphones)\n##\n(\"entity\"<|>VISION HOLDINGS<|>ORGANIZATION<|>Vision Holdings is a firm that previously owned TechGlobal)\n##\n(\"relationship\"<|>TECHGLOBAL<|>VISION HOLDINGS<|>Vision Holdings formerly owned TechGlobal from 2014 until present<|>5)\n<|COMPLETE|>\n\n######################\nExample 3:\nEntity_types: ORGANIZATION,GEO,PERSON\nText:\nFive Aurelians jailed for 8 years in Firuzabad and widely regarded as hostages are on their way home to Aurelia.\n\nThe swap orchestrated by Quintara was finalized when $8bn of Firuzi funds were transferred to financial institutions in Krohaara, the capital of Quintara.\n\nThe exchange initiated in Firuzabad's capital, Tiruzia, led to the four men and one woman, who are also Firuzi nationals, boarding a chartered flight to Krohaara.\n\nThey were welcomed by senior Aurelian officials and are now on their way to Aurelia's capital, Cashion.\n\nThe Aurelians include 39-year-old businessman Samuel Namara, who has been held in Tiruzia's Alhamia Prison, as well as journalist Durke Bataglani, 59, and environmentalist Meggie Tazbah, 53, who also holds Bratinas nationality.\n######################\nOutput:\n(\"entity\"<|>FIRUZABAD<|>GEO<|>Firuzabad held Aurelians as hostages)\n##\n(\"entity\"<|>AURELIA<|>GEO<|>Country seeking to release hostages)\n##\n(\"entity\"<|>QUINTARA<|>GEO<|>Country that negotiated a swap of money in exchange for hostages)\n##\n##\n(\"entity\"<|>TIRUZIA<|>GEO<|>Capital of Firuzabad where the Aurelians were being held)\n##\n(\"entity\"<|>KROHAARA<|>GEO<|>Capital city in Quintara)\n##\n(\"entity\"<|>CASHION<|>GEO<|>Capital city in Aurelia)\n##\n(\"entity\"<|>SAMUEL NAMARA<|>PERSON<|>Aurelian who spent time in Tiruzia's Alhamia Prison)\n##\n(\"entity\"<|>ALHAMIA PRISON<|>GEO<|>Prison in Tiruzia)\n##\n(\"entity\"<|>DURKE BATAGLANI<|>PERSON<|>Aurelian journalist who was held hostage)\n##\n(\"entity\"<|>MEGGIE TAZBAH<|>PERSON<|>Bratinas national and environmentalist who was held hostage)\n##\n(\"relationship\"<|>FIRUZABAD<|>AURELIA<|>Firuzabad negotiated a hostage exchange with Aurelia<|>2)\n##\n(\"relationship\"<|>QUINTARA<|>AURELIA<|>Quintara brokered the hostage exchange between Firuzabad and Aurelia<|>2)\n##\n(\"relationship\"<|>QUINTARA<|>FIRUZABAD<|>Quintara brokered the hostage exchange between Firuzabad and Aurelia<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>ALHAMIA PRISON<|>Samuel Namara was a prisoner at Alhamia prison<|>8)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>MEGGIE TAZBAH<|>Samuel Namara and Meggie Tazbah were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>DURKE BATAGLANI<|>Samuel Namara and Durke Bataglani were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>MEGGIE TAZBAH<|>DURKE BATAGLANI<|>Meggie Tazbah and Durke Bataglani were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>FIRUZABAD<|>Samuel Namara was a hostage in Firuzabad<|>2)\n##\n(\"relationship\"<|>MEGGIE TAZBAH<|>FIRUZABAD<|>Meggie Tazbah was a hostage in Firuzabad<|>2)\n##\n(\"relationship\"<|>DURKE BATAGLANI<|>FIRUZABAD<|>Durke Bataglani was a hostage in Firuzabad<|>2)\n<|COMPLETE|>\n\n######################\n-Real Data-\n######################\nEntity_types: organization,person,geo,event\nText: ml.\n\nMediante la anamnesis y otras pruebas complementarias debe demostrarse a priori la ausencia de otras enfermedades que cursen con hiperandrogenismo o clínica similar al ovario poliquístico, como la oligoamenorrea, el uso de medicamentos androgenizantes, la determinación de 17-OH-progesterona, el cortisol libre urinario (CLU) o salival, la prolactina o las hormonas tiroideas. Ante un hiperandrogenismo grave, de rápida evolución, o con niveles de testosterona plasmática total mayores de 2 ng/ml (o de 1 ng/ml en posmenopáusicas) o DHEA-S mayor de 6.000 ng/ml (>4.000 en posmenopáusicas) o de 2,5 veces el límite superior de la normalidad hay que indicar pruebas de imagen (ecografía, TAC, RNM) en busca de una tumoración gonadal o suprarrenal. Considerando la relación existente entre el hiperandrogenismo ovárico y el hiperinsulinismo, las pacientes con SOP son más resistentes a la insulina que las que no lo tienen, sean o no obesas. Podemos objetivarlo mediante la determinación del índice HOMA, que se encontrará elevado, por la presencia de criterios clínicos de síndrome metabólico (hipertensión arterial, dislipidemia, obesidad de predominio abdominal y alteraciones del metabolismo hidrocarbonado), y por su asociación con comorbilidades como la esteatosis hepática o el síndrome de apnea del sueño. Las pacientes con disfunción ovárica e hiperandrogenismo bioquímico son las que presentan más repercusiones clínicas y metabólicas. Las que presentan menos repercusión son las que solo padecen disfunción ovulatoria y ecografía de ovario poliquístico.\n\nReferencias:\n- Bulun SE. Physiology and Pathology of the female reproductive axis. En: Melmed S, Polonsky KS, Larsen P y Kronenberg H, eds. 13.ª ed. Williams Textbook of Endocrinology. Philadelphia: Elsevier; 2016. p. 590-663.\n- Legro RS. Evaluation and Treatment of Polycystic Ovary Syndrome. En: Feingold KR, Anawalt B, Boyce A, et al., eds. Endotext [Internet]. South Dartmouth (MA): MDText.com, Inc.; 2000. Disponible en: https://www.ncbi.nlm.nih.gov/books/NBK278959/ [Updated 2017 Jan 11].\n- Ortiz-Flores AE, Luque-Ramírez M, Escobar-Morreale HF. Síndrome de ovario poliquístico en la mujer adulta. Med Clin (Barc) [Internet]. 2019. Disponible en: http://www.sciencedirect.com/science/article/pii/S0025775318307474\n\n## 6.6 Transexuales\n\nEn un hombre adulto transexual (de mujer a hombre) en tratamiento con undecanoato de testosterona (1 g por vía i.m. cada 12 semanas), uno de los siguientes diagnósticos no tiene implicaciones sobre la decisión de interrumpir el tratamiento:\n\nA. Síndrome de apneas del sueño.\nB. Pancreatitis.\nC. Cardiopatía isquémica con angina inestable e insuficiencia cardíaca.\nD. Eritrocitosis.\n\n### COMENTARIO\n\nLa testosterona es el tratamiento hormonal de elección en el transexual varón (de mujer a hombre) para conseguir virilización y amenorrea. Se usa generalmente por vía parenteral (cipionato o propionato 100-200 mg/2 semanas, o undecanoato 1g/12 semanas), aunque también hay disponible en gel (1,6%, 50-100 mg/día) o parches transdérmicos (2,5-7,5 mg/día), para alcanzar los niveles propios de los varones.\n\nCon la testosterona se consiguen efectos androgénicos como el aumento de masa muscular y tejido magro con aumento de peso, aumento del pelo con distribución varonil (cara, tórax y abdomen), y disminución de la grasa cambiando a una distribución abdominal. La voz se hace más grave, aumenta el clítoris y la libido. La mucosa del endometrio se atrofia por lo que suelen desaparecer las reglas.\n\nNo obstante, la testosterona tiene efectos adversos potenciales que es necesario vigilar, cuyos riesgos son:\n- Muy altos: eritrocitosis.\n- Moderadamente altos: disfunción hepática grave (aumento de transaminasas 3 veces más que en límite superior de normalidad), enfermedad coronaria o cerebrovascular, HTA, cáncer de mama o útero.\n\nEl aumento de la grasa visceral y la disminución de la grasa subcutánea asociada a insulinorresistencia es perjudicial, por cuanto se asocia con el perfil del síndrome metabólico (obesidad abdominal, dislipemia, HTA y\n######################\nOutput:", "parameters": {"model": "gpt-4o-mini", "temperature": 0.0, "frequency_penalty": 0.0, "presence_penalty": 0.0, "top_p": 1.0, "max_tokens": 4000, "n": 1}, "history": null}